Literature DB >> 31826980

PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus.

Xue Han1, Matthew D Vesely1,2, Wendy Yang1, Miguel F Sanmamed1, Ti Badri1, Jude Alawa1, Francesc López-Giráldez3,4, Patricia Gaule5, Sang Won Lee1, Jian-Ping Zhang1, Xinxin Nie1, Ala Nassar1, Agedi Boto1,5, Dallas B Flies1, Linghua Zheng1, Tae Kon Kim1,6, Gilbert W Moeckel5, Jennifer M McNiff2,5, Lieping Chen7,2,6.   

Abstract

Systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE) of the skin are autoimmune diseases characterized by inappropriate immune responses against self-proteins; the key elements that determine disease pathogenesis and progression are largely unknown. Here, we show that mice lacking immune inhibitory receptor VISTA or programmed death-1 homolog (PD-1H KO) on a BALB/c background spontaneously develop cutaneous and systemic autoimmune diseases resembling human lupus. Cutaneous lupus lesions of PD-1H KO mice have clustering of plasmacytoid dendritic cells (pDCs) similar to human DLE. Using mass cytometry, we identified proinflammatory neutrophils as critical early immune infiltrating cells within cutaneous lupus lesions of PD-1H KO mice. We also found that PD-1H is highly expressed on immune cells in human SLE, DLE lesions, and cutaneous lesions of MRL/lpr mice. A PD-1H agonistic monoclonal antibody in MRL/lpr mice reduces cutaneous disease, autoantibodies, inflammatory cytokines, chemokines, and immune cell expansion. Furthermore, PD-1H on both T cells and myeloid cells including neutrophils and pDCs could transmit inhibitory signals, resulting in reduced activation and function, establishing PD-1H as an inhibitory receptor on T cells and myeloid cells. On the basis of these findings, we propose that PD-1H is a critical element in the pathogenesis and progression of lupus, and PD-1H activation could be effective for treatment of systemic and cutaneous lupus.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31826980     DOI: 10.1126/scitranslmed.aax1159

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  37 in total

1.  Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model.

Authors:  Yoon Mee Yang; Zhijun Wang; Michitaka Matsuda; Ekihiro Seki
Journal:  Arch Pharm Res       Date:  2021-01-24       Impact factor: 4.946

Review 2.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 3.  Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.

Authors:  Stinne Ravn Greisen; Bent Deleuran
Journal:  Curr Rheumatol Rep       Date:  2021-03-02       Impact factor: 4.592

Review 4.  A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.

Authors:  Ahmed Habib; Matthew Pease; Chowdari V Kodavali; Nduka Amankulor; Pascal O Zinn
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

5.  CDK4/6 inhibitor palbociclib reduces inflammation in lupus-prone mice.

Authors:  Yongfeng Zhang; Ben Jin; Haiyan D Miller; Dongxia Ge; Xin Zhang; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

Review 6.  Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

Authors:  Nan Yang; Zeyu Chen; Xilin Zhang; Yuling Shi
Journal:  BioDrugs       Date:  2021-07-02       Impact factor: 5.807

Review 7.  Sex Differences in Glioblastoma Immunotherapy Response.

Authors:  Juyeun Lee; Kristen Kay; Katie Troike; Manmeet S Ahluwalia; Justin D Lathia
Journal:  Neuromolecular Med       Date:  2021-04-17       Impact factor: 3.843

Review 8.  Immunopathogenesis of skin injury in systemic lupus erythematosus.

Authors:  Grace A Hile; J Michelle Kahlenberg
Journal:  Curr Opin Rheumatol       Date:  2021-03-01       Impact factor: 5.006

9.  VISTA is an activating receptor in human monocytes.

Authors:  Bryan M Rogers; Laura Smith; Zoltan Dezso; Xu Shi; Enrico DiGiammarino; Denny Nguyen; Sunantha Sethuraman; Pingping Zheng; Donghee Choi; Dong Zhang; Andrew Nguyen; Kathleen McGuire; Wei Liu; Namjin Chung; Debra T Chao; Shiming Ye; Gabriel R Starbeck-Miller
Journal:  J Exp Med       Date:  2021-06-09       Impact factor: 14.307

Review 10.  The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.

Authors:  Negar Hosseinkhani; Afshin Derakhshani; Mahdi Abdoli Shadbad; Antonella Argentiero; Vito Racanelli; Tohid Kazemi; Ahad Mokhtarzadeh; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.